百奥泰与STADA就托珠单抗注射液签署商业化协议，首付及里程碑款最高至1.36亿欧元 百奥泰发布关于与STADA就BAT1806(托珠单抗)注射液签署授权许可与商业化协议的公告。披露公司将 BAT1806（托珠单抗） 注射液在欧盟、瑞士、英国、其它部分欧洲国家、部分中东与北非地区 （MENA）和部分独立国家联合体（CIS）国家市场的独占的产品商业化权益有偿许可给 STADA。 首付款及里程碑款总金额最高至 1.36 亿欧元，其中包括 850 万欧元首付款、累计不超过 1.275 亿欧元里 程碑付款，以及净销售额的两位数百分比作为收入分成。该协议的签订预计将对公司未来业绩产生积极 影响，有利于提升公司全球商业化及盈利能力。 时代天使否认爱齐科技的专利侵权指控，称将积极应诉 时代天使发布声明。表示公司坚决否认爱齐科技提出的专利侵权指控，并将积极应诉。 "时代天使在二十多年的历史中，拥有以临床驱动创新的丰富传统。竞争对手的专利指控毫无根据，完 全站不住脚。"时代天使首席商务官兼高级副总裁 Rich Hirschland 表示，"自公司成立以来，我们一直在 专利合规上投入大量资源。我们坚信将在此案件中胜出。我们预计公 ...

Investment Rating - The report maintains a "Buy" rating for several companies in the biotechnology sector, including Legend Biotech (LEGN US), and others like 3SBio (1530 HK), Innovent Biologics (1801 HK), and more, indicating a positive outlook for these stocks [7]. Core Insights - The upcoming centralized procurement of biosimilars in mainland China is expected to impact multiple major products, with the first round of information collection already initiated [2]. - The report emphasizes that the impact of this procurement on company performance and product sales will likely be felt starting in 2026, as the process is expected to take longer due to the novelty of biosimilar procurement in China [2]. - Companies such as China Biologic Products, Innovent Biologics, and Hengrui Medicine are highlighted as key players with multiple products involved in the procurement process, warranting close attention to pricing and allocation results [2][3]. - The report suggests that the impact on innovative drugs will be limited, as the products involved in the procurement are off-patent and already have competing biosimilars [2]. Summary by Sections Section: Centralized Procurement - The centralized procurement for biosimilars is officially starting, with a focus on eight monoclonal antibody products [2]. - The information collection phase is expected to last 1-2 months, with a longer timeline anticipated for rule formulation and final product inclusion [2]. Section: Company Focus - Key companies to watch include China Biologic Products, Innovent Biologics, and Hengrui Medicine, with respective products in the procurement process [2]. - The report recommends monitoring the pricing and allocation outcomes closely for these companies [2]. Section: Innovative Drugs - The report indicates that the eight monoclonal antibodies involved in the procurement are already off-patent and have existing biosimilars, suggesting limited impact on innovative drugs still under patent [2]. - Continuous attention is advised for the upcoming national medical insurance negotiations and the establishment of commercial insurance innovative drug directories [2].